Professor Michael Cheung is a practicing Paediatric Cardiologist in Melbourne, Australia. Having worked in the NHS, Canadian and Australian healthcare systems, he is currently the Director of Cardiology and Leader of the Heart Research Group at the Murdoch Children's Research Institute. His clinical work is at the Royal Childrens Hospital and with the Adult Congenital Heart team at the Royal Melbourne Hospital. His research has included clinical trials and he has published 9 book chapters and >200 manuscripts.  Michael is the Paediatric representative of the Victorian Cardiac Network and the Chair of the Paediatric Executive of the Cardiac Society of Australia and New Zealand.

His deep expertise in clinical research trials as well as networked knowledge of the Australian landscape will support Phaim’s groundbreaking work in entering human trials for its Type 1 Diabetes treatment.

“Phaim Pharma's novel AIM therapy will help people living with Type 1 Diabetes all over the world. I am thrilled to be supporting its clinical journey as it enters the clinic, leveraging my several decades of experience in large national and multinational clinical trials. Making clinically relevant, best-in-class solutions for autoimmune disease is at the heart of this development, and I look forward to the next steps in this very worthwhile journey.”